Zimbus Breezhaler (indacaterol;glycopyrronium;mometasone furoate)
- Region
- 🇪🇺 EU
- Active substance
- indacaterol;glycopyrronium;mometasone furoate
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Asthma
- CHMP opinion
- Thu 30 Apr 2020
- EU approval
- Fri 03 Jul 2020
- Application
- EMEA/H/C/005518
- ATC
- R03AL
- Official record
- www.ema.europa.eu
Indication
Maintenance treatment of asthma in adults whose disease is not adequately controlled.
Regulatory milestones
No milestones recorded in the last year.
Follow Zimbus Breezhaler
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.